XML 37 R22.htm IDEA: XBRL DOCUMENT
v3.21.1

Equity | 12 Months Ended
--- | ---
Dec. 31, 2020
Stockholders' Equity Note [Abstract] |
EQUITY |
NOTE 14:- | EQUITY
| a. | The Ordinary shares of the Company are listed on the NASDAQ Global Select Market in the United States and are traded on the Tel-Aviv Stock Exchange in Israel.
| b. | Stock Option Plans:
Under the Company’s 2007 Stock Option Plan, as amended (“the 2007 Plan”), options may be granted to employees, officers, directors and consultants of the Company and its subsidiaries. Pursuant to the original 2007 Stock Option Plan, the Company reserved 1,500,000 Ordinary shares for issuance. In 2012, the Company increased the number of Ordinary shares reserved for issuance under the 2007 Plan by additional 1,000,000 Ordinary shares. On December 31, 2015 the Company’s Board of Directors increased the amount of Ordinary shares reserved for issuance under the 2007 Plan by additional 250,000 Ordinary shares and extended the 2007 Plan by 10 years whereas it will expire on August 1, 2027. As of December 31, 2020, an aggregate of 932,500 Ordinary shares of the Company are available for future grants under the 2007 Plan. Each option granted under the 2007 Plan is exercisable for a period of ten years from the date of the grant of the option. The exercise price for each option is determined by the Board of Directors and set forth in the Company’s award agreement. Unless determined otherwise by the Board of Directors, the option exercise price shall be equal to or higher than the share market price at the grant date. The options generally vest over 3-4 years. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2007 Plan. A summary of employee option activity under the 2007 Plan as of December 31, 2020 and changes during the year ended December 31, 2020 are as follows:
|  | Number of options |  |  | Weighted average exercise price |  |  | Weighted average remaining contractual term (in years) |  |  | Aggregate intrinsic value |
Outstanding at January 1, 2020 |  |  | 119,767 |  |  | $ | 2.58 |  |  |  | 1.37 |  |  | $ | 1,171 |
Granted |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Exercised |  |  | (95,517 | ) |  |  | 2.28 |  |  |  |  |  |  |  |  |
Forfeited |  |  | - |  |  |  |  |  |  |  |  |  |  |  |  |
Outstanding at December 31, 2020 |  |  | 24,250 |  |  | $ | 3.45 |  |  |  | 1.24 |  |  | $ | 380 |
Exercisable at December 31, 2020 |  |  | 24,250 |  |  | $ | 3.45 |  |  |  | 1.24 |  |  | $ | 380 |
The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders exercised their options on December 31, 2020. This amount is changed based on the market value of the Company’s Ordinary shares. Total intrinsic value of options exercised during the years ended December 31, 2018, 2019 and 2020 was $617, $537 and $765, respectively. As of December 31, 2020, there was no unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Plans. The options outstanding as of December 31, 2020, have been separated into ranges of exercise price categories, as follows:
Exercise price |  | Options outstanding |  |  | Weighted average remaining contractual life (years) |  |  | Weighted average exercise price |  |  | Options exercisable |  |  | Weighted average exercise price of exercisable options |
In $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2.01-3 |  |  | 18,000 |  |  |  | 0.77 |  |  | $ | 2.94 |  |  |  | 18,000 |  |  | $ | 2.94 |
4.01-5 |  |  | 6,250 |  |  |  | 2.60 |  |  | $ | 4.94 |  |  |  | 6,250 |  |  | $ | 4.94 |
|  |  | 24,250 |  |  |  | 1.24 |  |  | $ | 3.45 |  |  |  | 24,250 |  |  | $ | 3.45 |
| c. | Accumulated other comprehensive income (loss):
|  | December 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
Accumulated realized and unrealized gain (loss) on available-for-sale securities, net |  | $ | - |  |  | $ | 1 |  |  | $ | (94 | )
Accumulated foreign currency translation adjustments |  |  | 7,809 |  |  |  | (351 | ) |  |  | (6,057 | )
Accumulated unrealized gain on derivative instruments, net |  |  | 26 |  |  |  | 26 |  |  |  | 26 |
Total other comprehensive income (loss) |  | $ | 7,835 |  |  | $ | (324 | ) |  | $ | (6,125 | )
| d. | Dividend distribution policy
On August 9, 2017, the Company’s Board of Directors decided to amend the dividend distribution policy announced in 2012. According to the Company’s amended policy, each year the Company will distribute a dividend of up to 75% of its annual distributable profits. The Company’s Board of Directors may at its discretion and at any time, change, whether as a result of a one-time decision or a change in policy, the rate of dividend distributions and/or decide not to distribute a dividend, all at its discretion. On February 22, 2017, the Company declared a dividend distribution of $ 0.085 per share ($ 3,775 in the aggregate) which was paid on April 5, 2017. On August 13, 2017, the Company declared a dividend distribution of $ 0.13 per share ($ 5,779 in the aggregate) which was paid on September 13, 2017. On February 28, 2018, the Company declared a dividend distribution of $ 0.13 per share ($ 5,785 in the aggregate) which was paid on March 26, 2018. On August 8, 2018, the Company declared a dividend distribution of $ 0.155 per share ($ 7,563 in the aggregate) which was paid on September 5, 2018. On March 4, 2019, the Company declared a dividend distribution of $ 0.15 per share ($ 7,335 in the aggregate) which was paid on March 25, 2019. On August 13, 2019, the Company declared a dividend distribution of $ 0.156 per share ($ 7,628 in the aggregate) which was paid on September 12, 2019. On May 26, 2020, the Company declared a dividend distribution of $ 0.08 per share ($ 3,918 in the aggregate) which was paid on June 25, 2020. On August 13, 2020, the Company declared a dividend distribution of $ 0.175 per share ($ 8,585 in the aggregate) which was paid on September 10, 2020.

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration